Features and outcomes from a retrospective study of 570 hospitalized Chinese patients with drug-induced liver injury - 21/02/18
páginas | 9 |
Iconografías | 2 |
Vídeos | 0 |
Otros | 0 |
Summary |
Aims |
To investigate the clinical features and outcomes of hospitalized patients with drug-induced liver injury (DILI).
Methods |
The medical records of hospitalized patients with DILI from January 1997 through July 2016 were reviewed.
Results |
Five hundred seventy cases were reviewed, of which 381 (66.8%) were female. Four hundred fifty-eight cases (80.4%) presented with hepatocellular injury, 53 (9.3%) with cholestatic injury and 59 (10.4%) with mixed injury. Chronicity was more common in cholestatic and mixed injury cases than in hepatocellular cases (P<0.001). In the hepatocellular injury group, patients in the severity score≥3 group were younger than the patients in the severity score≤2 group (P=0.040). In the entire cohort, 487/570 (85.4%) patients resolved, 57/570 (10.0%) developed chronic liver injury, and 11/570 (1.9%) died. Thirty-two acute DILI patients with severity scores of 3 received steroid therapy, but no improvement was observed in the recovery time or resolution rate of these patients compared with that of the non-steroid group. Chinese herbal medicines were the most commonly used drugs, followed by antimicrobials, cardiovascular agents, endocrine agents, and nonsteroidal anti-inflammatory drugs (NSAIDs).
Conclusions |
Hepatocellular injury was the most common DILI pattern, and 10.0% of patients developed chronic DILI. Steroid therapy was not associated with an improved recovery time or survival in acute severe DILI patients.
El texto completo de este artículo está disponible en PDF.Keywords : DILI, Clinical features, Steroid
Esquema
Vol 42 - N° 1
P. 48-56 - février 2018 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?